

Gaia Skibinski

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/10767152/publications.pdf>

Version: 2024-02-01

14
papers

2,129
citations

1039406

9
h-index

1125271

13
g-index

15
all docs

15
docs citations

15
times ranked

3705
citing authors

#	ARTICLE	IF	CITATIONS
1	The E3 ligase TRIM1 ubiquitinates LRRK2 and controls its localization, degradation, and toxicity. <i>Journal of Cell Biology</i> , 2022, 221, .	2.3	8
2	Generation of two human induced pluripotent stem cell lines from fibroblasts of Parkinsonâ€™s disease patients carrying the ILE368ASN mutation in PINK1 (LCSBi002) and the R275W mutation in Parkin (LCSBi004). <i>Stem Cell Research</i> , 2022, 61, 102765.	0.3	2
3	Generation of two human induced pluripotent stem cell lines from fibroblasts of unrelated Parkinsonâ€™s patients carrying the G2019S mutation in the LRRK2 gene (LCSBi005, LCSBi006). <i>Stem Cell Research</i> , 2021, 57, 102569.	0.3	2
4	Generation of two human induced pluripotent stem cell lines (iPSCs) with mutations of the Î±-synuclein (SNCA) gene associated with Parkinsonâ€™s disease; the A53T mutation (LCSBi003) and a triplication of the SNCA gene (LCSBi007). <i>Stem Cell Research</i> , 2021, 57, 102600.	0.3	0
5	iPS cells in the study of PD molecular pathogenesis. <i>Cell and Tissue Research</i> , 2018, 373, 61-77.	1.5	30
6	Nrf2 mitigates LRRK2- and Î±-synucleinâ€‘induced neurodegeneration by modulating proteostasis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017, 114, 1165-1170.	3.3	95
7	A Three-Groups Model for High-Throughput Survival Screens. <i>Biometrics</i> , 2016, 72, 936-944.	0.8	7
8	Targeting the Intrinsically Disordered Structural Ensemble of Î±-Synuclein by Small Molecules as a Potential Therapeutic Strategy for Parkinsonâ€™s Disease. <i>PLoS ONE</i> , 2014, 9, e87133.	1.1	126
9	Mutant LRRK2 Toxicity in Neurons Depends on LRRK2 Levels and Synuclein But Not Kinase Activity or Inclusion Bodies. <i>Journal of Neuroscience</i> , 2014, 34, 418-433.	1.7	124
10	Longitudinal measures of proteostasis in live neurons: Features that determine fate in models of neurodegenerative disease. <i>FEBS Letters</i> , 2013, 587, 1139-1146.	1.3	17
11	Drug discovery in Parkinson's disease: update and developments in the use of cellular models. <i>International Journal of High Throughput Screening</i> , 2011, 2011, 15.	0.5	19
12	Direct Membrane Association Drives Mitochondrial Fission by the Parkinson Disease-associated Protein Î±-Synuclein. <i>Journal of Biological Chemistry</i> , 2011, 286, 20710-20726.	1.6	499
13	Cytoplasmic Mislocalization of TDP-43 Is Toxic to Neurons and Enhanced by a Mutation Associated with Familial Amyotrophic Lateral Sclerosis. <i>Journal of Neuroscience</i> , 2010, 30, 639-649.	1.7	446
14	Mutations in the endosomal ESCRTIII-complex subunit CHMP2B in frontotemporal dementia. <i>Nature Genetics</i> , 2005, 37, 806-808.	9.4	752